Annual Report

Overview

The report highlights BioPorto's 11% sales growth in 2025 and the commercial launch of ProNephro AKI on Roche's Cobas c 501 for the US pediatric market. Consolidated 2025 revenue was DKK 40,287 thousand, while adjusted EBITDA was a loss of DKK 76,533 thousand.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 26 March 2026
Language: English
Pages
File size
Restatement: Disclosed

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services